GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » EV-to-FCF

GlobeStar Therapeutics (GlobeStar Therapeutics) EV-to-FCF : -4.53 (As of May. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GlobeStar Therapeutics's Enterprise Value is $0.95 Mil. GlobeStar Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.21 Mil. Therefore, GlobeStar Therapeutics's EV-to-FCF for today is -4.53.

The historical rank and industry rank for GlobeStar Therapeutics's EV-to-FCF or its related term are showing as below:

GSTC' s EV-to-FCF Range Over the Past 10 Years
Min: -126.55   Med: -58.71   Max: -1.12
Current: -4.53

During the past 13 years, the highest EV-to-FCF of GlobeStar Therapeutics was -1.12. The lowest was -126.55. And the median was -58.71.

GSTC's EV-to-FCF is ranked worse than
100% of 389 companies
in the Biotechnology industry
Industry Median: 6.49 vs GSTC: -4.53

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), GlobeStar Therapeutics's stock price is $0.00044. GlobeStar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.002. Therefore, GlobeStar Therapeutics's PE Ratio for today is At Loss.


GlobeStar Therapeutics EV-to-FCF Historical Data

The historical data trend for GlobeStar Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics EV-to-FCF Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.27 -12.57 -22.15 -8.22 -10.46

GlobeStar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.29 -29.93 -22.93 -10.46 -6.26

Competitive Comparison of GlobeStar Therapeutics's EV-to-FCF

For the Biotechnology subindustry, GlobeStar Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's EV-to-FCF falls into.



GlobeStar Therapeutics EV-to-FCF Calculation

GlobeStar Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.951/-0.21
=-4.53

GlobeStar Therapeutics's current Enterprise Value is $0.95 Mil.
GlobeStar Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlobeStar Therapeutics  (OTCPK:GSTC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

GlobeStar Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00044/-0.002
=At Loss

GlobeStar Therapeutics's share price for today is $0.00044.
GlobeStar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


GlobeStar Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550

GlobeStar Therapeutics (GlobeStar Therapeutics) Headlines

From GuruFocus

GlobeStar Therapeutics Corporation Update on Recent Activity

By ACCESSWIRE ACCESSWIRE 08-02-2022

AngioSoma Developing Male Enhancement Supplement

By Marketwired Marketwired 01-06-2020